Trial intelligence / Profile preview

Vorinostat and Etoposide in Pediatric Refractory Solid Tumors

NCT01294670Phase 2Completed

Sponsor
Memorial Sloan Kettering Cancer Center
Start
Feb 2011
Primary completion
Dec 2020
Modality
Covalent Small Molecules, Classical Binding Small Molecules
Countries
2
01

Overview

A Phase 2 trial of vorinostat in solid tumor, sarcoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Feb 2011; status: completed.

02

Drugs

vorinostat
03

Conditions

solid tumorsarcoma

Beyond the preview

Go deeper on NCT01294670.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01294670.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call